Evidence map›Paper›PMID 38804255›Full record

ArticleChemical communications (Cambridge, England)2024

Quinoline-based tetrazolium prochelators: formazan release, iron sequestration, and antiproliferative efficacy in cancer cells.

Yu-Shien Sung, Elisa Tomat

Abstract read
In one paragraph

Article in Chemical communications (Cambridge, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Disulfide-based 2-pyridyl-hydrazone prochelators induce iron deprivation and oxidative stress in ovarian cancer cells.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yu-Shien SungDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721-0041, USA. tomat@arizona.edu.
Elisa TomatDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721-0041, USA. tomat@arizona.edu.ORCID http://orcid.org/0000-0002-7075-9501

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
Coordination chemistry approaches to target cellular metal dysregulationR35GM153364 · NIGMS · UNIVERSITY OF ARIZONA · PI TOMAT, ELISA · 2024 to 2025
$723k
NCI NIH HHS P30 CA023074NIGMS NIH HHS R35 GM153364
6 · The paper itself

Abstract

Iron-binding strategies in anticancer drug design target the key role of iron in cancer growth. The incorporation of a quinoline moiety in the design of tetrazolium-based prochelators facilitates their intracellular reduction/activation to iron-binding formazans. The new prochelators are antiproliferative at submicromolar levels, induce apoptosis and cell cycle arrest, and impact iron signaling in cancer cells.

Indexed as

Antineoplastic AgentsApoptosisCell ProliferationIronQuinolinesCell Cycle CheckpointsCell Line, TumorDrug Screening Assays, AntitumorHumansMolecular StructureAntineoplastic AgentsIronquinolineQuinolines

Identifiers

PMID38804255
PMCPMC11568512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.